Kazia Therapeutics Limited

Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications.

Our lead program is paxalisib (formerly GDC-0084), a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, paxalisib entered a phase II clinical trial in 2018. Interim data was reported in April 2020, and further data is expected in 2H 2020. Paxal

ASX Code

KZA

View CCR Kazia Report

 

Company news

We help investors gain insights into your company through high quality research reports.

We provide a full suite of corporate access services.

 
 
 
Corporate Connect Research

79 Kent Street
Millers Point
Sydney NSW 2000

Email us

Contact us

13 + 11 =